![](https://pharmafile.com/wp-content/uploads/2023/11/shutterstock_1968508504-1024x683.jpg)
ERS Genomics and IRBM sign license agreement for CRISPR/Cas9
Betsy Goodfellow | May 20, 2024 | News story | Research and Development | CRISPR/Cas9, ERS Genomics, IRBM, License Agreement, Pharmacy
ERS Genomics and IRBM have announced that they have entered into a non-exclusive CRISPR/Cas9 license agreement, granting IRBM access to ERS Genomics’ CRISPR/Cas9 patent portfolio.
Financial details of the agreement have not yet been disclosed.
IRBM is a drug discovery CRO with a focus from target validation to finding preclinical candidates, spanning indications such as oncology, neurology and infectious diseases. Meanwhile, ERS Genomics often provides licensing to CRISPR/Cas9 technology for other companies, covering CRISPR/Cas9 use in all cells, including eukaryotic and prokaryotic cells.
John E Milad, chief executive officer at ERS Genomics, commented: “We are committed to supporting cutting-edge research and expanding the horizons of medical innovation by providing companies such as IRBM with the ability to take advantage of CRISPR/Cas9 technology. We look forward to seeing the innovative ways in which our gene editing technology will be utilised in various stages of drug discovery, providing candidates for a wide range of therapeutic areas.”
Carlo Toniatti MD PhD, chief scientific officer at IRBM, added: “We are committed to delivering high quality drugs by leveraging our broad range of expertise and capabilities across the entire preclinical drug discovery continuum. With the integration of CRISPR/Cas9 gene editing technology we are increasing our capability to identify and validate potential drug targets, to generate more predictive pre-clinical models and to elucidate the mechanisms of action of novel therapeutics.”
Betsy Goodfellow
Related Content
![](https://pharmafile.com/wp-content/uploads/2023/07/cdc-LiNIONbajm4-unsplash-300x200.jpg)
Provectus Biopharmaceuticals announces license agreement with University of Miami
Provectus Biopharmaceuticals has announced that it has entered into an exclusive worldwide license agreement with …
![](https://pharmafile.com/wp-content/uploads/2023/05/shutterstock_266216168-300x200.jpg)
Rhythm Pharmaceuticals and LG Chem Life Sciences enter license agreement
Rhythm Pharmaceuticals and LG Chem Life Sciences have announced that they have entered into a …
![](https://pharmafile.com/wp-content/uploads/2023/05/shutterstock_138095450_33-300x200.jpg)
Gilead and Compugen enter exclusive license agreement for immunotherapy programme
Gilead Sciences and Compugen have announced that they have entered an exclusive license agreement for …